NanoSphere Health Sciences Inc. (CSE:NSHS, “NanoSphere”) is pleased to announce that, in response to growing demand for the NanoSphere’s Evolve NanoSerum™ product, its Colorado license partner has increased production capacity at its facility.

“NanoSerum is a state-of-the-art formulation that carries a full spectrum of cannabinoids and phytochemicals with precision-metered dosing, every time,” said Dr. Richard Kaufman, NanoSphere’s Chief Science Officer. “This development is an extremely encouraging sign of market demand for new methods for cannabinoid delivery.”


“This is a watershed moment for our business,” added David Sutton, NanoSphere’s Chief Operating Officer and President. “Our partner achieved the capacity increase by switching to an ethanol distillation process whereby the facility can process 30,000 units per month.”

NanoSphere is commercializing its disruptive, next-generation nanoparticle cannabis delivery system platforms under the brand Evolve Formulas. In July 2017, Evolve Formulas launched its acclaimed NanoSerum product, the first clinically tested transdermal cannabis product to relieve pain in minutes, for the adult use and medical cannabis markets in Colorado.

“As our company gains recognition in the market place, more and more customers are discovering and embracing our necessary delivery technology,” NanoSphere Chairman and CEO Robert Sutton added. “The re-order rate of our Evolve NanoSerum product is testament to its quality and effectiveness.”

Evolve products are available in more than 70 accounts and are expected to be in over 250 accounts by year end throughout Colorado.  Additionally, NanoSphere will be expanding to qualified manufacturers and operators in several states to license our delivery technology and bring the Evolve brand to new U.S. and Canadian markets, as well as, build on that success by further introducing new product applications.  Each product application will deliver a unique pharmacokinetic and pharmacodynamic profile of cannabinoid activity and therapeutic applications.

About NanoSphere
NanoSphere Health Sciences LLC, a wholly owned operating subsidiary of the Company, is a biotechnology firm specializing in the creation of the NanoSphere Delivery System™, a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond. The patent-pending NanoSphere Delivery System™ represents one of the most important developments for advancing the non-invasive and user-friendly delivery of biological agents in over 25 years. For more information on NanoSphere, please visit http://www.nanospherehealth.com.

On behalf of the Board:
Robert Sutton, Chairman & CEO
rsutton@nanospherehealth.com

PR Contact:
Anne Donohoe / adonohoe@kcsa.com / 212-896-1265
Anne Szustek Talbot / atalbot@kcsa.com / 212-896-1210

Investor Contact:
David Sutton, President & COO / dsutton@nanospherehealth.com / 303.887.9300
Victor Goncalves, Executive Vice President /vgoncalves@nanospherehealth.com / 204-997-5517

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

Forward Looking Statement Caution
This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company’s intentions, plans, estimates, expectations or beliefs regarding the future. Although the Company believes that any forward looking statements in this news release are reasonable, there can be no assurance that any such forward looking statements will prove to be accurate. The Company cautions readers that all forward looking statements, including without limitation those relating to the Company’s future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements. Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements. Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements, whether as a result of new information, future events or otherwise.

Click here to connect with NanoSphere Health Sciences (CSE:NSHS) for an Investor Presentation.

Source: www.newswire.ca

Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development

Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.

Keep reading... Show less

The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.

With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.

DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.

Keep reading... Show less

CFN Enterprises Inc. (OTCQB: CNFN) (CFN Media) partners with FMW Media Works LLC to produce a regular series on the global cannabis markets to air on major financial news networks across the US. Initial segment features leading cannabis analyst and US Multi-State Operator (MSO)

CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced that its inaugural news segment on the cannabis markets, “Cannabis Market Outlook for 2021,” will air on Bloomberg, Newsmax and Fox Business.

Keep reading... Show less